334 replies to this topic

[ImmInst]

PropThink: Stem Cell Divestiture May Benefit Geron Shareholders More than the ...
Reuters - Oct 18, 2012

By Jake King. Geron Corp (NASDAQ:GERN) may have finally found a buyer for its suspended stem cell program. The company has been searching since November of 2011 when Geron halted the projects to focus on the development of Imetelstat and ...

View the full article

[ImmInst]

Geron Acknowledges Letter to its Stockholders from BioTime
Reuters - Oct 19, 2012

MENLO PARK, Calif., October 19, 2012 -- Geron Corporation (Nasdaq: GERN) today acknowledged the public release by BioTime, Inc. (NYSE: BTX) of a letter to Geron's stockholders regarding Geron's stem cell assets.

View the full article

[ImmInst]

Zacks Reiterates Neutral on Geron (GERN)
Jags Report - 31 minutes ago

Geron Co. logo Zacks reissued their neutral rating on shares of Geron (NASDAQ: GERN) in a report released on Thursday. Zacks currently has a $1.50 target price on the stock.

Geron (GERN) Q3/12 and 1st 9 months Results - Proactive Investors USA & Canada

View the full article

[ImmInst]

Geron Posts Narrower Loss
Zacks.com - Oct 31, 2012

Geron Corporation (GERN - Analyst Report) posted a net loss of 13 cents per share in the third quarter of 2012, narrower than the Zacks Consensus Estimate of a loss of 14 cents and the year-ago loss of 16 cents.

View the full article

[ImmInst]

Pharmaceutical Companies To Spend Large Amounts on Research of Cancer ...
News Today - Nov 1, 2012

Pharmaceutical Companies Nuclear energy is one of the major energy sources for the present generation of industries, especially in Medicine for the role of nuclear reactors.

3 Companies With Investment Potential In Targeting Cancer - Seeking Alpha

View the full article

[ImmInst]

PropThink: Geron Q3 Earnings Review: Waiting Not for Godot, but for San ...
Reuters - Nov 5, 2012

By Ivan Deryugin. When a biotechnology company is around 20 years after its incorporation, common wisdom would suggest that it has become a major player in the biotechnology sector, with at least one blockbuster drug on the market.

View the full article

[ImmInst]

Geron Announces Non-Binding Letter of Intent with BioTime Regarding Stem ...
Reuters - 1 hour ago

Thu Nov 15, 2012 4:15pm EST. MENLO PARK, Calif., November 15, 2012 -- Geron Corporation (Nasdaq: GERN) today announced that the company has entered into a non-binding letter of intent (LOI) with BioTime, Inc. (NYSE: BTX) and BioTime's recently ...

UPDATE: BioTime, Geron Enter Deal on Stem Cell Assets - Benzinga
Biotech outfit Geron nears spinoff of stem cell business - FierceBiotech

View the full article

[ImmInst]

Healthcare Review: Celldex Therapeutics, Geron, Brookdale Senior Living ...
Equities.com - 56 minutes ago

Geron Corporation(NASDAQ:GERN) stock climbed 2.48% to $1.24. The company announced that the company has entered into a non-binding letter of intent (LOI) with BioTime, Inc. and BioTime's recently formed subsidiary, BioTime Acquisition Corporation ...

View the full article

[ImmInst]

Geron to sell embryonic stem cell business to BioTime
San Francisco Business Times (blog) - 55 minutes ago

Geron Corp. will sell its shuttered embryonic stem cell assets to BioTime Inc., according to a non-binding letter of intent signed by the companies.

View the full article

[ImmInst]

Geron-BioTime Sign LOI - Analyst Blog
NASDAQ - Nov 16, 2012

A year after announcing its decision to exit stem cell therapy, Geron Corporation ( GERN ) announced that it has entered into a non-binding letter of intent (LOI) with BioTime, Inc. ( BTX ) and BioTime`s subsidiary, BioTime Acquisition Corporation (BAC ...

View the full article

[ImmInst]

GERON CORPORATION : Geron Announces Non-Binding Letter of Intent with ...
4-traders - Nov 15, 2012

MENLO PARK, Calif., November 15, 2012 -- Geron Corporation (Nasdaq: GERN) today announced that the company has entered into a non-binding letter of intent (LOI) with BioTime, Inc. (NYSE: BTX) and BioTime's recently formed subsidiary, BioTime ...

View the full article

[ImmInst]

Geron Discontinues GRN1005 and Restructures to Focus on Imetelstat ...
Reuters - 16 minutes ago

Company to Host Conference Call at 8:30 a.m. ET on Tuesday, December 4. MENLO PARK, Calif., December 3, 2012 - Geron Corporation (Nasdaq: GERN) today announced that the company has discontinued development of GRN1005, its peptide-drug ...

Geron to discontinue brain-cancer drug development - MarketWatch
Geron drops brain cancer drug, to cut jobs - Chicago Tribune

View the full article

[ImmInst]

Geron (NASDAQ:GERN) Announces To Halts Brain-Cancer Drug - GERN ...
Galaxy Stocks - 2 hours ago

Geron Corporation (NASDAQ:GERN) stock's trade at beginning with a price of $1.45 and throughout the trading session climbed at a high of $1.48 other than when day-trade ended the stock finally advanced +4.96% to $1.48.

View the full article

[ImmInst]

Geron Scraps GRN1005, Cuts Jobs - Analyst Blog
InvestorIdeas.com (press release) - 4 hours ago

Geron Corporation (GERN - Analyst Report) faced another pipeline setback recently with the company deciding to scrap the development of its phase II oncology candidate, GRN1005.

View the full article

[ImmInst]

Geron Presents Positive Results from Phase 2 Study of Imetelstat in Essential ...
Reuters - 2 hours ago

MENLO PARK, Calif., December 10, 2012 - Geron Corporation (Nasdaq: GERN) today announced positive clinical results from the Phase 2 trial of imetelstat, the company's first-in-class telomerase inhibitor, in patients with essential thrombocythemia (ET).

View the full article

[ImmInst]

GERON CORPORATION : Geron Presents Positive Results from Phase 2 Study ...
4-traders - Dec 10, 2012

MENLO PARK, Calif., December 10, 2012 - Geron Corporation (Nasdaq: GERN) today announced positive clinical results from the Phase 2 trial of imetelstat, the company's first-in-class telomerase inhibitor, in patients with essential thrombocythemia (ET).

View the full article

[ImmInst]

GERON CORPORATION : Geron to Divest Stem Cell Assets
4-traders - 1 hour ago

MENLO PARK, Calif., January 7, 2013 -- Geron Corporation (Nasdaq: GERN) today announced that on January 4, 2013, it entered into an Asset Contribution Agreement (the "Agreement") with BioTime, Inc. (NYSE: BTX) and BioTime's recently formed ...

BioTime Signs Definitive Agreement With Geron Regarding Stem Cell Assets - DailyFinance
Geron (GERN) To Sell Stem Cell Assets To Biotime (BTX) Subsidiary - iStockAnalyst

View the full article

[ImmInst]

Geron's Update on Stem Cell Assets - Analyst Blog
NASDAQ - 1 hour ago

Geron Corporation ( GERN ) announced that it has signed an Asset Contribution Agreement with BioTime, Inc. ( BTX ) and BioTime's recently formed subsidiary, BioTime Acquisition Corporation (BAC).

BioTime Submits Protocol for Initiation of Human Clinical Trials of Renevia ... - DailyFinance

View the full article

[ImmInst]

Gerons Update on Stem Cell Assets
Zacks.com - Jan 10, 2013

Geron Corporation (GERN - Analyst Report) announced that it has signed an Asset Contribution Agreement with BioTime, Inc. (BTX) and BioTime's recently formed subsidiary, BioTime Acquisition Corporation (BAC).

View the full article

[ImmInst]

UPDATE: Piper Jaffray Initiates Geron Corporation at Overweight on Risk/Reward
Benzinga - 55 minutes ago

Piper Jaffray initiated coverage on Geron Corporation (NASDAQ: GERN) with a Overweight rating and a $3.00 price target. Piper Jaffray commented, "Geron is focused on developing drugs from its novel telomerase-inhibitor platform and its 1st-in-class ...

View the full article

[ImmInst]

2 Big Gainers: Sirius XM Radio Inc(NASDAQ:SIRI), Geron Corporation(NASDAQ ...
Mesh Press (press release) - 35 minutes ago

Shares of Geron Corporation(NASDAQ:GERN) rose by 5 cents or 3.01% to $1.71 in the morning session after its coverage was initiated by Piper Jaffray with an Overweight rating and a $3.00 price target saying that they view substantial growth for the ...

View the full article

[ImmInst]

Hot Stocks in Focus: Geron Corporation (NASDAQ:GERN), Molycorp Inc (NYSE ...
Cogo - 16 hours ago

On January 4, 2013, Geron entered into an Asset Contribution Agreement with BioTime, Inc. and Asterias Biotherapeutics, Inc. The closing of the transaction was subject to certain approvals by BioTime`s shareholders, the effectiveness of certain ...

View the full article

[ImmInst]

Geron stem cell work finds new home, reunited with Tom Okarma
San Francisco Business Times (blog) - Oct 1, 2013

In a complex stock-swapping and intellectual property deal, including a new subsidiary called Asterias Biotherapeutics Inc.

View the full article

[ImmInst]

Investors Alert: Geron Corporation (NASDAQ:GERN), Inovio Pharmaceuticals Inc ...
SBWire (press release) - 1 hour ago

On January 4, 2013, Geron entered into an Asset Contribution Agreement (the "Agreement") with BioTime, Inc. (NYSE: BTX) and Asterias Biotherapeutics, Inc. (formerly known as BioTime Acquisition Corporation). The closing of the transaction was subject ...

View the full article

[ImmInst]

Geron Corporation (NASDAQ:GERN) Stock Has Posted 76% Gain In 30 days
FinancialsTrend - 6 hours ago

Asterias is a 100% owned subsidiary of BioTime, Inc. This deal was originally announced in January of this year. In exchange of Geron's human embryo stem cell practice, Aserias has allotted Geron 6.53 million Seriers A common stock.

View the full article

[ImmInst]

BIOTIME, INC. : BioTime's Subsidiary OncoCyte Corporation and The Wistar ...
4-traders (press release) - 1 hour ago

BioTime, Inc. (NYSE MKT: BTX), and its subsidiary OncoCyte Corporation today announced that OncoCyte has entered into a Sponsored Research Agreement and a Material Transfer Agreement with The Wistar Institute to collaboratively develop lung cancer ...

View the full article

[ImmInst]

Research and Markets: Global Stem Cells Market Report 2013-2018: Adult Stem ...
Business Wire (press release) - 58 minutes ago

The company profiles for some of the key players, namely Advanced Cell Technology Inc., STEMCELL Technologies Inc., Cellular Engineering Technologies Inc., BioTime Inc., Aastrom Biosciences Inc. and California Stem Cell Inc. in terms of company ...

View the full article

[ImmInst]

Geron (Nasdaq: GERN) Shares Skyrocket, Coverage Initiated with a Buy
Benzinga - 2 hours ago

On January 4, 2013, GERN entered into an Asset Contribution Agreement with BioTime, Inc. and Asterias Biotherapeutics, Inc. (formerly known as BioTime Acquisition Corporation).

View the full article

[ImmInst]

BioTime begins development of new products based on HyStem hydrogel ...
pharmabiz.com - Oct 7, 2013

BioTime, Inc, a biotechnology company engaged in research and product development in the field of regenerative medicine, has initiated the development of two new products based on its HyStem hydrogel technology platform.

View the full article

[ImmInst]

Geron Corporation Reports Third Quarter 2013 Financial Results
Wall Street Journal - 1 hour ago

On October 1, 2013, the transaction to divest Geron's human embryonic stem cell assets pursuant to the terms of the previously announced Asset Contribution Agreement that was entered into in January 2013 with BioTime, Inc. and BioTime's subsidiary, ...

View the full article